

Big Idea
CONNECTpreneur

**VIRTUAL ROCKET
PITCH + POWER
NETWORKING**

**21
NOVEMBER
IIAM - IPM EST**

CONNECTPRENEUR.ORG

AGENDA

11:00 - 11:05 AM

VIRTUAL NETWORKING

11:05 - 11:15 AM

WELCOME & INTRODUCTIONS

- TIEN WONG, Founder and Host, CONNECTpreneur Community
- SKYLAR RALLISON, Community Manager, CONNECTpreneur

11:15 - 12:00 PM

ROCKET PITCH SESSION

Companies will be introduced by:

- SARA CLASPER Associate Attorney, NEXT powered by Shulman Rogers
- MARK HAAS, CEO, Association for Enterprise Growth

12:00 - 1:00 PM

PRESENTING COMPANY BREAKOUT ROOMS & VIRTUAL NETWORKING

PRESENTING COMPANIES



Alphyn Biologics, Inc. - Neal Koller



Arcato Laboratories - Jeff Miller



BraveHeart Wireless - Steve McCalmont



Scout - Michael Haddix



Everix Optical Filters - Hooman Banaei



20/20 Gene - Jonathan Cohen



iByte - Nicholas Fratantonio



NeuroEM - Amanda Patanow



Ovala - Stephen Bollinger



Quasi Robotics - Alena Shumova



ShipThrifty - Rob Williamson

SPEAKERS



TIEN WONG, CEO, OPUS8, INC. @tienwong

Tien is CEO of Opus8, an investment and advisory firm which helps technology companies and alternative investment fund managers raise capital. He is also Chairman of Lumious, a leader in corporate tech training and learning analytics, as well as Chairman of Lore Systems, a provider of network engineering, cloud computing, and strategic IT consulting.

In 1991, Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition in 2003 by Affiliated Computer Services. CyberRep was one of the largest CRM outsourcing companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business unit is one of the world's largest call center operations, with nearly \$3 billion in revenue as divisions of Xerox, Conduent, and Continuum. CyberRep was ranked for 4 consecutive years in INC. Magazine's "Inc. 500" as one of the fastest-growing companies in the USA. CyberRep was profitable for 11 straight years and was backed by Allied Capital Corporation.

Tien is a recognized international expert in CRM, direct marketing, and BPO, having presented at dozens of industry events around the world on CRM and BPO topics. He has provided industry commentary on the ABC, Fox, NBC, CNBC, Maryland Public Television, and China's CCTV networks, as well as Time Magazine, The Washington Post, Inc. Magazine, and Success Magazine. He serves on several boards including the Montgomery County (MD) Economic Development Corp., Center for Innovation Technology GAP Fund's Investment Advisory Board, Junior Achievement, and Refraction. He was appointed by Governor Martin O'Malley to the 9-member Maryland Venture Fund Authority which allocates and manages over \$130 million of capital which is invested into top-tier venture funds and startups. He is an Entrepreneur in Residence at Georgetown University's McDonough School of Business, and a graduate of Dartmouth College.



SKYLAR RALLISON, COMMUNITY MANAGER, CONNECTPRENEUR

Skylar Rallison is a dynamic professional who wears multiple hats as the Community Manager for CONNECTpreneur and Business Analyst for Opus8. She graduated from The Marriott School of Business at Brigham Young University with a degree in Entrepreneurial Management. She has many years of experience in Business Management, Social Media Marketing/Management, Data Analytics, Business Leadership, and Project Management. With a diverse skill set and a passion for facilitating connections and driving business growth, Skylar thrives in the intersection of Community Management and Strategic Analysis.

Skylar enjoys her current role at CONNECTpreneur, which hosts the world's largest monthly investor pitch events as well as 1/2-day Forums with upwards of 900 RSVPs, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Skylar is pivotal in fostering engagement and building relationships within the investor and entrepreneur community. She creates inclusive digital spaces where members can share insights, collaborate on opportunities, and build a supportive network. Her role includes but is not limited to, team management, event coordination, project management, and marketing.

She also enjoys her current role as a business analyst at Opus8. Opus8 assists companies and fund managers (private equity, VC, and hedge funds) raise private capital from family offices, UHNW individuals, and institutions. Skylar leverages her analytical mindset and attention to detail to provide valuable insights for Opus8. Through her meticulous analysis of investment opportunities and industry research, Skylar helps drive informed decision-making, enabling Opus8 to curate high-quality events that bring together investors and promising ventures.



Alphyn Executive Summary

Breakthrough Drug of Choice for Atopic Dermatitis (Eczema)

Multi-Target Therapeutics™
A New Class of Drugs
More Powerful Therapeutics

MANAGEMENT TEAM

Neal Koller – Chairman & CEO
President & CEO, Board of Directors, life science businesses, **last exit at 16x**; Sr. Exec. Wyeth

Steven Pentelink – President
P&G Exec. managed **\$1B early tech portfolio**, global manager \$750M Beauty Care Products

Gary Pekoe, PhD – Chief Scientific Officer
Director for several multinational pharma companies, led development & approval of 1st & market leading topical antibiotic **Bactroban®**, lead clinical trial protocol writer for **Keytruda®**, 20 years clinical and regulatory adviser to pharma

Jazmyne Mink – Regulatory Affairs Manager
8 years' experience with Alphyn's AB-101

OPERATIONAL PARTNERS

Eagle Analytic - Analytics Lab
Emery Pharma - Chemistry & Microbiology Lab
World Class Ethnobotanist
World Class Botanical Chemistry & Analytics Lab
DDL - Formulation and Manufacture
PCCA - Formulation and Manufacture
Multiple Geo-local Agri Partners
TagOne - Supply Chain Management
Accelagen - Regulatory and Clinical Trials (AUS)
Symbio - Regulatory and Clinical Trials (US, EU)
DLA Piper - IP and Legal Worldwide
EisnerAmper - Finance and Tax (US)
Artus GmbH - Finance and Tax (EU)
RDI Partners - Finance and Tax (Australia)

SCIENCE ADVISORS

12 Global KOL Dermatologists

Dennis P. West, PhD
Prof Emer, Derm, Feinberg Sch of Med, Northwestern Univ

Peter Coderre
FDA IND & NDA Microbiology Reviewer (retired)
Scientific Advisory Board, CARB-X (BARDA, NIAID, NIH)
Antimicrobial Regulatory Consulting LLC

Patric Lundberg, PhD
Past Associate Prof, Microbiology/Molecular Cell Biology
Eastern Virginia Medical School

Shekhar Mitra, PhD
Sr VP, Global Innovation, Procter & Gamble (retired)
President, InnoPreneur, LLC

FUNDING TO DATE

Founders \$ 870 K (not capitalized)
Seed \$ 1.1 M (Convertible Note)
Pre-equity \$ 2.5 M (Convertible Note)
Series A \$ 5.5 M (Series A)
Non-dilutive \$ 1.9 M

FINANCING OPEN & MILESTONES

Series B \$18.0 M; **\$7M raised**
Lead Investor in place, diligence available
Complete Phase 2b AD Infected Trial - **FUNDED**
Complete 4x increase drug raw material - **FUNDED**
Complete Phase 2b AD Standard Trial
Complete 2nd drug Phase 2 Trial (EB - Orphan Drug)

COMPANY OVERVIEW


Alphyn is using its zabalafin (AB-101) drug platform to develop dermatological therapeutics with fewer side effects, greater patient tolerability and that are more effective, initially for Atopic Dermatitis (AD), and following for Epidermolysis Bullosa (EB). Zabalafin is a new class of drugs named Multi-Target Therapeutics™ providing unique multiple mechanisms of action from multiple bioactive compounds for multiple ways to treat an individual disease, to be more effective, and multiple diseases that can be treated. After only 3½ years of operation Alphyn's 1st drug candidate, topical zabalafin hydrogel, completed 2 Phase 2a clinical trials in AD confirming faster path to regulatory approval in the huge AD commercial opportunity. Clinical results better than competitive drugs point to "drug of choice" for this vast \$118 Billion market ⁵ with potential 800 million patient population ¹.

THE PROBLEMS IN TREATING AD

- 60.5% of adults report severe itch
- 67% of children and 33% of adults report significant sleep disturbances, poor quality of life ²
- 55 % report inadequate disease control ²
- 8.3-year life reduction with hospitalizations primarily due to AD bacteria-associated problems ³

TWO SUCCESSFUL PHASE 2a CLINICAL TRIALS: ZABALAFIN ADVANTAGES

- Most important - itch superior to competition
- Only AD drug to directly treat itch and the critical Bacteria Component of AD
- 90% of patients report significant improvement in Quality of Life
- 35% better reduction in inflammation versus dominate market leader (IGA)
- Side effect reduction and patient tolerability superior to competition
- Strong safety data resulted in: Waiver of Phase 1 clinical trial; Phase 2 clinical trials start age 2
- Clinical results point to 'Drug of Choice' for AD



MULTIPLE MARKET PROTECTION STRATEGIES

- Patent exclusivity potential to 2042: US & Worldwide, Composition of Matter, Methods of Use
- Regulatory exclusivity possible: 10 years USA, 8 years Europe & Japan
- No FDA generic drug competition possibility
- Estimated 15 year robust drug raw material supply protection: Quantity, Contracts, Regulatory

VAST AND GROWING AD MARKET

Drug (Company)	Time on Market	Annualized Sales ⁴	Estimated Patient # ⁵
Dupixent® (Sanofi)	4 years	\$7 Billion	~ 270,000
Opzelura® (Incyte)	2 years	\$380 Million	~ 103,500

AD STRONG COMPARABLE EXIT DEALS

Acquired / Licensed	When	Exit: Cash plus Milestones	Exit Stage
Proteologix (by J&J)	May '24	\$850 Million + Milestones	Pre-clinical
Kyowa Kirin (by Amgen)	Jun '21	\$1.25 Billion	Phase 2 clinical trial
Kymab (by Sanofi)	Jan '21	\$1.45 Billion	Phase 2 clinical trial

Value Proposition

Huge market / huge problem: 5 million Americans have wisdom teeth extracted each year. Existing pain options are highly addictive (opioids) or ineffective (OTC). There is nothing on the market like ARC-001 – a unique, proprietary, sustained release formulation gel combining Benzocaine, Lidocaine, and Bupivacaine. Arcato has a global exclusive license, has scaled manufacturing, is entering human clinical trials, and plans to exit in ~12 months via acquisition.

Company Background

- Raised >\$3 million in private capital + non-dilutive grants to gain FDA approval of IND, complete pre-clinical work, and scale manufacturing
- Use of proceeds: complete first-in-human clinical trial (mid-2025)
- Exit strategy: acquisition (end-2025); already rejected one acquisition offer; three partners expressing interest in commercial license

Leadership Team

- >100 years in the biotech and dental industry
- Michael Jay – Founder – 40 years in drug development & formulation
- Jeff Miller – Chairman & CEO – 28 years in biotech industry
- Alan Parr – Chief Technology Officer – >35 years in biotech industry
- Shannon Wallet – Advisor (University of Florida; UNC)
- Kevin Byrd – Advisor (University of Michigan; UNC)

Product

- ARC-001: unique, proprietary, sustained release formulation gel combining 3 medications that have been in humans for decades
- In development for pain management after wisdom tooth surgery
- Administered as one-time dose directly into socket following extraction that is projected to provide 5-7 day extended pain relief

Special Know-How

- Patents filed patents in all major territories (USA, Europe, Japan, etc.)
- No gels of this nature in development; all other options are injectable
- Patent lawyer has issued highly favorable report for the technology

Market

- USA: 10 million wisdom teeth extracted each year; 70% are managed by the oral surgeon specialty – assume 30% market share
- Peak USA revenue ~\$250 million; double that for global revenue

Distribution Channels

- Direct sale to oral surgeons/dentists via distributor (as it is today)
- Promotion will be handled through typical channels: sales force, marketing materials, online, conferences; DTC is attractive option

Competition

- Primary mechanisms for pain control today are opioids, Advil, Tylenol – addictive/ineffective
- All new therapies in development are injectable; ARC-001 is the only gel (topical) treatment
- 95% of wisdom tooth surgery patients surveyed said they would be likely to ask about a new pain product

Financial Projections (Unaudited):

	2024	2025	2026	2027	2028
Revenue	0	0	0	\$15 million	\$40 million
EBIT	n/a	n/a	n/a	\$3 million	\$15 million

Quick Facts

Company Name: Arcato

Contact: Jeff Miller

Address: 1800 North Greene St., Suite E, Greenville, NC 27834

Phone: 203-450-0163

Email: jeff@arcatolabs.com

Website: n/a

Industry: Biotech

Bank: Truist

Law Firm: Walter Daniels

Patents: TBD

Number of Employees: 1

Leadership Team: 3

Amount of Raise: \$1.5 million

Current Investors: Private syndicate of experienced investors and executives

Use of Funds: Conduct Phase 1/2 clinical trial; target exit in 9-12 months

AI Driven Congestive Heart Failure Monitoring from Home



Worldwide Market Opportunity: \$62B

The Bravo1™ platform is the cornerstone in building extensive at-home chronic care monitoring revenue streams. With an initial focus on Congestive Heart Failure, our goal is to partner with Clinics, MedTech companies, Telehealth organizations and other providers who are interested in quickly and efficiently bringing a remote chronic care solution to their customers.

The Problem


Hospitals are in crisis due to extreme staffing shortages of both doctors and nurses. It's an ugly situation that no one wants to highlight – but the data tells the story. Some hospitals are supporting only 60% of their beds. When those beds are filled with chronic care patients, the hospitals aren't making much money. Managing heart failure through the emergency room creates one of the largest cost centers (loss) of any hospital system. Congestive Heart Failure (CHF) costs in the United States are expected to be at least \$70 billion per year by 2030, with the total cost of caring for HF patients approaching \$160 billion (AHA). The US CHF market in 2023 was \$6.6B, which represents a forecasted CAGR of 40.1% over this decade. CHF costs in the United States are expected to be at least \$70 billion per year by 2030, with the total cost of caring for HF patients approaching \$160 billion (AHA). With a 2023 US CHF market of \$6.6B, that represents a CAGR of 40.1% over this decade. Rural hospitals are being affected by this disproportionately.

The Solution

Clinicians and patients need actionable, timely information, not more data...

AI on-the-edge makes it possible!

With BraveHeart's unique sensor platform and proprietary AI algorithms, providers receive early warning in advance of patient decline. Clinics can manage more **congestive heart failure** patients with fewer staff AND improve patient outcomes.



Personalize, Predict, and Prevent

From the Hospital to the Home

Target Markets

The BraveHeart Bravo1 platform can be customized for many applications including Remote Chronic Care, Hospital-at-Home, mHealth, Telemedicine. With 3 sources of revenue, the business model is compelling and proven in the industry. Device, PaaS Services and Professional Services are the backbone of our revenue projections.

The Value\$ Chain



FOR PROVIDERS & INSURERS

- Expand Revenue & Margins with Remote Chronic Care
- Reduce Hospital days and re-admissions while improving patient outcomes
- Maximize clinician efficiency
- Reduce insurers total cost to serve



FOR OUR PARTNERS

- Create new offerings from a single platform
- Establish technology differentiation with best-in-class platform
- Drive additional therapeutics revenues from Remote Chronic Care Patients



BRAVEHEART WIRELESS

- Monthly Recurring Revenue PaaS Subscription Model
- Device + Analytics + Integration Services revenue streams
- Opportunity for many to monetize data

Seeking a minimum of \$10M to optimize AI algorithms, expand beta studies, drive commercialization

Stage: Series A extension

- \$10M
- + Convertible note
- Raised a \$5.6M seed round
- Grow with current Beta customers
- Build commercialization team
- Expand IP

Achievements to Date

- 510(k) clearance
- Partnerships and investments from Industry leaders, J&J-Abiomed & ADI
- Beta customers
- Issued patents

Why Invest?

- 28% CAGR: Telemedicine
- \$62B WW Market
- Experienced team
- Platform Powered Solution
- Foundation for growth and scale

Target Customers:

- Chronic Care Clinics (CHF)
- Remote Cardiac Monitoring Service Providers
- TeleHealth Companies
- Pharma / CRO's

Regulatory Path

- Class II Device/510(k)

Team



Steve McCalmont, CEO
Ralph Beck, VP SW
David Shimkus, VP OPS
Dave Centauro, CFO
Michael Courtemanche, SW Adv.
Jay Barrows, Commercial Adv.

Contact

Steve McCalmont
(603) 930-5481
stevem@braveheart.life

Company Name: Everix Inc.

City, State: Orlando, FL
 Phone: (407) 923 - 3260
 Website: www.everixopticalfilters.com
 Presenter: Hooman Banaei, PhD.
 Email: hooman@everix.co
 #Of Employees: ~20 FTE



Everix enables mass deployment of compact personal health and technology devices with features that were not affordable in the past. We turn inexpensive polymer into a nanomaterial (**optical filter**) that is worth **20x the value of GOLD by weight**. We make it **10x-100x more cost efficiently, 70x more energy efficiently, and 20x more compact** than our competition. With **37 patents** and a full manufacturing operation, we are serving top-tier **Fortune 50 customers** in markets such as medical devices, consumer electronics or industrial sensing.

Problems

1- Filter size limits product miniaturization and sensor sensitivity; 2- Rigid form-factor; 3-Insufficient economies of scale for mass markets. Current manufacturing technologies have hit an innovation plateau despite many unmet needs.

Technology & Products

Technology: To meet the need for lower-cost, high-volume optical filters, we have developed a process that replaces traditionally expensive vacuum deposition with a much less expensive thermal drawing tower. Like the process for drawing glass optical fibers from cylindrical preforms, we create planar preforms and draw the layers to sub-wavelength thicknesses needed to create any desired interference filtering effect.

Product Lines (filters): Notch, Bandpass, Dichroic, Edge, Absorptive, Hybrid. Products currently sold via distributors or directly to customers.

Unique Value Proposition

Device miniaturization (e.g., smart watches); New form factors (e.g., ingestible sensing capsules); Enabling price-elastic markets (e.g., home-based personal infection/cancer testers); Short lead time for high volume (time sensitive consumer electronic product release); Freedom of material choice (to meet application-based requirements).

Business Model

1- Sales of standard products in beachhead markets directly and through multiple sales channels. (markets: medtech, sensors).
 2- Sales of customized products to key players in AR/VR. (markets: AR/VR, consumer electronics)
 3- IP licensing in other markets (markets: eyewear, smart glass, solar control, solar generation, display/cinema).

Competition

Everix has a unique, patented technology, which fills the gap between:
 1. Traditional vacuum coating companies, all using patent-expired technologies (Viavi Solutions, Materion, Semrock, Alluxa, Omega, Chroma).
 2. Multilayer film extrusion industry – primarily for non-filter applications and low-performance filtering (such as display back-reflectors) due to process nature limitations (3M, PeakNano, Toray).

Investment Opportunity

Current Round: **\$3M bridge to profitability** round. Approx. 50% invested or committed.

Use of funds

Reaching operational profitability, new hires, strategic IP portfolio expansion, working capital for consistent production of standard products, boosted sales and marketing of standard products into beach head markets, continued IP protection.

Team

Hooman Banaei, PhD, CEO/Founder – Optics PhD. Family manufacturing business with 500 employees.

Jess Brown, PhD, Sales & Business Development Director - 20 years in sales and business development in optics and electronics industries.

Andy Moyle, Director of Operations - 8 years in manufacturing improvement and management.

Karolina Wojtas, Director of Strategic Development - 5 years in VC, 3 years of operational experience in startups, ex-founder.

Market

TAM: **\$50B+**
 Beachhead emerging markets: Consumer Medtech (\$1.6B), Consumer Electronics (\$4.3B) IoT and Automotive sensors (LiDAR, etc.) (\$2.5B)
 Future blue ocean markets: eyewear, smart glass, solar control, solar generation, display/cinema.

Financials

Revenue: 7-figures cumulative revenue from initial product sales and PoC. Fortune 50 paying customers.



20/20 GeneSystems, Inc.
15810 Gaither Dr., Suite 235
Gaithersburg, MD 20877

www.2020gene.com

www.OneTestforCancer.com

Key Strengths:

- Our approach is substantially more **affordable, accessible, and accurate** for early-stage cancer detection than the leading DNA based MCED on the market.
- 2023 Inc.5000 Fastest Growing Company in Maryland.
- Strong patent position covering screening w/ machine learning + tumor antigens.
- Utilizes FDA approved instruments and kits.
- Pilot w/ leading supermarkets.
- Sophisticated Shareholder Base: Including DigitalDx, Fujifilm (via acquisition), PingAn Ventures, Morgan Stanley (via Acquisition), Brevet Capital, Keiretsu Capital, and leading Family Offices.
- Board and management team have many successful exits.
- IPO ready w/ PCAOB audits and other compliance in place; engagement with reputable investment bankers
- Periodic acquisition inquiries from Fortune 500 industry leaders.
- Growing revenues permit royalty-based financing models w/ guaranteed ROI.

Contact:

investors@2020gene.com

(240) 453.6339 ext. 102

Executive Summary

20/20 GeneSystems, Inc. is a clinical laboratory test developer focused on AI-powered blood tests for the early detection and prevention of cancers and chronic diseases. We are currently the #2 market leader in the U.S. for multi-cancer early detection (MCED) blood tests. Our flagship product, ***OneTest™ for Multiple Cancers***, is seeing rapid adoption in the MCED marketplace with **ten consecutive quarters of accelerated sales growth**.

The Problem: Screening is not widely available or utilized for most of the leading cancer killers, such as those of the lungs, pancreas, ovaries, and liver. To address this void, MCEds are now available and generating significant enthusiasm among many medical authorities, policy makers, employers, and consumers. Up until now, these tests have been expensive, hard to access, and miss most cancers at their earlier stages when they can often be effectively treated.

Our Solution & Advantages: *OneTest™* is the first and only MCED on the market that (i) is available for under \$200, (ii) can be accessed at home without painful needles, and (iii) has been demonstrated in studies conducted in 2024 by the U.S. National Cancer Institute to correctly identify significant numbers of otherwise deadly **cancers at an early stage**. These cancers include those of the lung, pancreas, and ovaries, which, when detected at an earlier stage, give the best chance of survival.

The Market: In the U.S. alone, the market for MCEds is expected to exceed several billion dollars per year by the end of this decade following anticipated coverage by Medicare starting in 2028. There is also a substantial overseas market, especially throughout East Asia where demand for new types of early cancer screening is high.

Our Progress:

- Over 15,000 tests sold in the past three years.
- Revenues doubling yearly; 10 consecutive quarters of increasing sales growth.
- Line-of-sight to profitability.
- Growing adoption among employers and consumers.
- Additional revenues already coming from license agreement w/ clinical testing laboratories in Taiwan and Japan.

New Products: AI powered ***OneTest for Longevity*** will track biomarkers of chronic inflammation associated with 8 of 10 leading causes of death and offer specific diet and exercise changes proven to lower biomarker levels and related disease risk.



Executive Summary

Company Overview: Founded by Nicholas Fratantonio DDS FAGD, a seasoned dentist with over 40 years of experience, iDentalFy/iByte, U.S. PATENT issued, (International Pat-Pend.) introduces an evolutionary concept in personal safety with its innovative dental wearable technology. iByte is poised to address a critical global issue of missing, abducted, trafficked, and unidentified individuals, particularly children, through a pioneering approach in personal safety.

Product Description: iByte is the world's smallest personal safety wearable device, designed as a transparent, tooth-colored veneer with an embedded nano-microprocessor. This cutting-edge technology enables location tracking, identification, authentication, and facilitates swift search and rescue operations. The device is easily adhered to an upper permanent molar in under 90 seconds and pairs with a smartphone app for seamless functionality.

Unique Selling Proposition: Unlike conventional wearable devices, iByte is semi-permanent, securely embedded, and self-charging, ensuring it cannot be lost, left behind, or stolen. Its discreet design makes it virtually undetectable, offering unparalleled peace of mind to users and their families. iByte aims to keep loved ones safe, secure, and out of harm's way with its reliable and unobtrusive technology.

Market Opportunity: With an estimated 35 million people worldwide affected by issues of abduction, trafficking, and unidentified status annually, iByte addresses a profound gap in public safety. By leveraging dental medicine and cutting-edge technology, iByte pioneers a new category of personal safety devices that have the potential to save countless lives globally.

Vision and Mission: iByte's mission is encapsulated in the motto "Never Lost Again." It aims to prevent the tragedy of missing persons by providing a proactive and effective solution that integrates seamlessly into everyday life. By combining dental expertise with advanced technological innovation, iByte is committed to making a significant impact on global public health and safety.

Conclusion: In conclusion, iByte represents a profound advancement in personal safety technology, rooted in decades of dental expertise and a deep commitment to safeguarding individuals worldwide. With its unique approach and unparalleled functionality, iByte is poised to redefine the landscape of personal safety devices, offering peace of mind and security to families everywhere.

Contact: For more information about iByte and its revolutionary technology, please contact Nicholas Fratantonio DDS FAGD at Nicholasfrat@gmail.com.

Disclaimer: iByte is currently Patent protected, and the information provided is subject to change pending final product development and regulatory approvals.



NeuroEM's first-of-its-kind device offers a safe, effective, and non-invasive approach to treating neurodegenerative diseases, including Alzheimer's, and protecting brain health throughout the aging process.

www.NeuroEM.com

Alzheimer's is among the costliest conditions to society

- Worldwide, **55M people** are living with Alzheimer's.
- Nearly **7M Americans** have Alzheimer's. **500,000 more** are diagnosed each year.
- Medicare spends 3 times more** for beneficiaries with Alzheimer's.

NeuroEM will be a disruptive force in the Alzheimer's therapeutics market

There is no cure and treatment options are ineffective and difficult for patients and cost thousands of dollars per year.

- 5 of the 8 FDA-approved drugs do not affect the underlying brain changes that cause symptoms. **None are right for all patients.**
- Ongoing research exploring potential pharma options **remains uncertain.**


Human clinical studies showed cognitive stabilization or improvement in 7 of 8 AD sufferers within 2 months

Our Transcranial Electro-Magnetic Treatment using Radio Frequencies (TEMT-RF) alters three key factors at the root of cognitive decline:

- Detoxify the brain by disaggregating toxic Aβ and p-tau proteins
- Rebalance cytokines, indicating a reduction of inflammation in the brain and body
- Increase ATP—the source of energy for use and storage at the cellular level

Capital investment to date: \$7M+

Target Milestones



Investment Opportunity

NeuroEM is raising two rounds over the next two years:

- \$5M Seed Preferred today** to prepare the final product for launch; Target pre-money valuation: \$15M
- \$5-10M Series A Preferred in 2025** to launch the wellness product; Target pre-money valuation: \$30-45M

GLOBAL MARKET

ALZHEIMER'S THERAPEUTICS

\$4.05B
IN 2022

\$30.8B
IN 2033

DIGITAL BRAIN HEALTH

\$200B
IN 2022

\$413B
IN 2032

NOOTROPICS / SUPPLEMENTS

\$6.6B
IN 2022

\$11.4B
IN 2031

FROM RESEARCH TO COMMERCIALIZATION:

NeuroEM is transforming groundbreaking research into a commercially viable reality.

10+ Years of University Research

2 NIH Grants + More in progress

Patent portfolio includes **9 issued US patents** and **10 pending patent applications globally**

First to receive **FDA Breakthrough Device** status for the treatment of Alzheimer's

A **proven leadership team** and **medical advisory board** – all with a scientific or technology background, startup experience, and commercial expertise.

Startup Health Alzheimer's **Moonshot Community** Member



Contact

Chuck Papageorgiou, CEO
Chuck@NeuroEM.com
+1-727-252-6120



Opportunity Overview

Transaction Overview

Business Description:

Innovative women's health products company; OTC product portfolio focuses on women's Stress Urinary Incontinence (SUI) or Light Bladder Leaks (LBL)

Transaction:

Convertible Notes (25% discount) for early participants to Series B Investment \$10M

Market:

Hungry for an Over-the-Counter Solution to Women's health issue of bladder Leaks, 18M Women in US alone

Contact Information

Interested parties are encouraged to direct all communication with:

Steve Bollinger

President and CEO

sbollinger@userevive.com

+1 (724) 241.8937

+1(508) 942-6396



Ovala, Inc. (the "Company" or "Ovala") is seeking investment partner for its over-the-counter ("OTC") stress urinary incontinence ("SUI") product, Revive[®].

The Company was incorporated in 2019 in Pittsburgh, PA. Our focus, in this everchanging environment of healthcare has been to empower women to take back their healthcare through innovation. We have taken the next step by developing a medically proven technologies/approach in Women's health, that was once only available under a physician's care/Rx, through innovation, taking it directly to the end user.

Revive, is an Over the Counter, monthly kit that stops leakage for women from the inside out. It is a novel disposable urethral support(pessary) that comfortably and consistently counters the problem of SUI for women with best-in-class performance, comfort, and affordability. FDA clearance in 25 Jan 2019. The product entered the market Q4:2019. The Company desires an investor to help maximize value, exploit this growing area in women's health, and provide women with a discrete, non-surgical solution to bladder leakage/SUI. Strategic buyers are already aware and interested in next steps.

Opportunity Highlights

Market Size and Opportunity

- SUI – Urinary leaks when coughing, laughing or exercising – is the most prevalent form of incontinence among women, affecting ~18m adult women in the U.S.
- 1 in 4 women over the age of 18 experience episodes of involuntary urine leakage; 2 in 3 women who experience loss of bladder control do not currently use any treatment or product
- U.S. OTC vaginal pessary market, the initial market for Revive[®], is ~\$200m+

Revive[®] Differentiation

- **New Product Category in Incontinence**, current OTC solutions to SUI include absorbent pads and liner
- According to customer reviews, The Revive product is changing women's lives. As a "one size fits most," tampon-like device, Revive is a familiar and comfortable solution to those fundamental issues
- Pads and liners simply mask the effects of incontinence through absorption, while Revive treats the issue at its root cause and eliminates women's concerns about odor and discomfort
- Revive can transform how women manage SUI and impact both physiological and psychological
- **Healthcare providers also have CPT or reimbursement codes** for the product to benefit both the user and the healthcare provider
- Need technology, not a want. **Once you are a user, you will purchase monthly for many years, long term repeat use product.**

Proven Clinical Results

- The Revive pivotal U.S. study shows very positive consumer reaction and overall excitement
- Study results from the five clinics show a statistically significant improvement in quality of life, as well as a reduction in the number of episodes and overall leakage
- Equally significant, Revive addresses the current market's gap by providing a comfortable and easy to use device
 - 93% reported extreme ease of use
 - 92% reported that the device was a good fit upon first use
 - 75% achieved dry results
- **Authorization to Market with 510(k) for OTC distribution: 25 Jan 2019 (K183468)**
- Number 1 recommended product by Pelvic Floor Physical Therapist for SUI

Market Plan and Launch

- Initial launch into US commence www.Amazon.com, www.Walmart.com etc...; the product has been introduced with very positive acceptance – retailers asking for exclusivity
- **In revenue ~\$700k 2024**
- **Capital to Launch in US Retail, Healthcare Providers, and expand internationally**

Growth Platform

- This product comfortably and privately addresses a problem that is currently undertreated
- As more women feel comfortable seeking help for SUI, the consumer base grows
- Additional innovative line extensions can expand customer base and market size for Revive

Revive[®]

Value Proposition:

Affordable and dependable autonomous robotic carts designed to streamline operations. Eliminate inefficiencies caused by manual cart handling and replace them with a fully automated, self-driving solution for improved productivity and cost savings.

Company Background:

Founded in 2017 by Life Science and Engineering professionals, Quasi Robotics specializes in end-to-end design, assembly, and programming of Autonomous Mobile Robots (AMRs) at its Frederick, MD headquarters. Its proprietary Q.AI Intelligence software is continually updated to meet evolving customer needs, address customer's feedback, ensuring cutting-edge performance and adaptability across industries.

Leadership Team:

Vlad Lebedev: CEO; Tom Dolan CSO, Max Didenko: CTO

Products/Services:

Quasi designs the hardware and programs the Artificial Intelligence software for each of their autonomous solutions. Their main products are the Model C2 AMR, the Q.AI intelligence that powers all of its' functions, and the Cloud Connect Data Interface, which is a cloud-based application able to collect extensive data and traceability metrics for business intelligence.

Technologies/Special Know-How:

Quasi Robotics leverages proprietary AI software, including advanced machine learning models developed in-house, to power its Model C2 solution. With five patents pending and exclusive object detection/obstacle avoidance capabilities, years of research have established Quasi's Q.AI Intelligence as a key competitive advantage in the autonomous robotics market. No other company can do what we do 😊.

Market: Quasi Robotics targets the \$39.6 billion automated material handling market, growing at 12-15% annually. Focused on manufacturing, warehousing, healthcare, and SMEs, Quasi offers cost-effective automation with revenue from Model C2 sales and services and cross-licensing, positioning it for success in this expanding market.

Distribution Channels: Quasi Robotics uses a hybrid distribution strategy combining a direct salesforce, channel partners, and VARs. Key distributors include Horizon Sales (East Coast), Midwest (Wolter, Inc) and West Coast (LogicBus), ensuring nationwide market coverage and seamless product delivery. International coverage in Canada and Mexico/Latin America. Europe pending.

Competition: Wheel.Me, MuL Technologies, Fetch Robotics, Omron Robotics, Others

Quasi Robotics operates in a rapidly evolving market for autonomous mobile robots (AMRs), delivering cost-effective and reliable robotic cart solutions tailored to streamline operations across industries. Positioned as a nimble competitor, Quasi bridges the gap between affordability and advanced functionality, addressing inefficiencies in manual material handling with ease of deployment and robust autonomy.

Quick Facts**Company Name:**

Quasi Robotics, Inc.

Contact:

Alena Shumova, Marketing Director
Vlad Lebedev, CEO

Address:

321 Ballenger Center Dr. Suite 210
Frederick, MD, 21703

Email: info@quasi.ai

Website: www.quasi.ai

Industry: Robotics Manufacturing

Law Firm: Two law firms and one individual attorney

Patents: 5 Patent Pending

Number of Employees: 14

Amount of Financing Sought: \$1m

Current Amount Raised: \$2.0m

Use of Funds:

To fund order fulfillment with

Value Proposition

Scout is the only fintech solution serving college athletic departments as well as student athletes in the NIL era. Scout provides payment rails for athletic departments as well as a consumer fintech experience for college athletes.

Company Background:

Scout is a fintech solution selling enterprise level software solutions to college athletic departments. Scout provides payment processing, salary cap tools, and fintech solutions for college athletes. Scout is the only fintech solutions serving athletic departments and athletes in the space.

Leadership Team: *CEO and Cofounder, Michael Haddix is a former Division 1 basketball star and the son of a first-round NFL draft pick and 8-year NFL veteran. Haddix has a unique understanding of the financial challenges and opportunities athletes face. Prior to founding Scout, Haddix worked at Octagon, where he managed the wealth of high-profile professional athletes, including Chris Paul, Stephen Curry and Michael Phelps.*

Haddix holds an MBA from Columbia Business School and began his career as an investment banker at Goldman Sachs, where he honed his financial acumen before transitioning to his true passion: empowering athletes through financial education and wellness.

Cofounder and CTO, Cindy Zeng has built and is leading the product development and engineering team at Scout. Prior she led web technologies as sole front-end engineer and helped spearhead the first enterprise product into beta at Citizen. She has helped build, design and manage products for various companies. She got her BS from Carnegie Mellon University.

Products/Services: *College athletes will make over \$5B in income in 2025 and have no tool solving their unique challenges (i.e. paid as independent contractors, no financial experience, short earning window, lack of financial education. Scout solves this unmet need. Next year, college athletic programs will distribute up to \$22M directly to players and need a fintech solution to process payments and provide visibility to multiple stakeholders. Scout is the only end to end solution.*

Technologies/Special Know-How: *Scout provides automatic tax withholding, automatic investing and saving, and a highly personalized and proprietary financial education curriculum developed by the founder through his unique experience in the sports space. Scout is the only education meets execution platform built for gen z athletes and has no current competitors.*

Market: *Our target is current college athletes and college athletic programs. There are over 360 division 1 programs and over 500,000 current college athletes of which 30% graduate each year and their sports are replaced. Scout has a TAM of athletes which is infinitely growing. Scout charges from \$50k-400k to college athletic programs and then monetizes each player individually for life.*

Distribution Channels: *We charge athletic programs who make it mandatory for their student athletes. We are paid to acquire customers.*

Competition: *Scout competes with traditional financial advisors who target the 1% of high earning college athletes, but no one is targeting the 99%. We are competing with a group who has never banked before.*

Quick Facts

Company Name: Scout

Contact: Michael Haddix

Address:

9 Wintergreen Court Clifton Park, NY 12065

Phone: 215-279-3202

Email:

mike@elevatewith.com

Website: scoutffw.com

Fintech

Bank: Mercury

Law Firm: BDH

Number of Employees: 7

Leadership Team: Michael

Haddix, CEO

Cindy Zeng, CTO

Amount of Financing

Sought: 1M

Current Investors:

Chingona Ventures, Chris

Paul, Hustle Fund, Reach

Capital, J4 Ventures

Use of Funds: Banking

Partner, Team growth,

revenue growth

Financial Projections (Unaudited):

	2024	2025	2026	2027
Revenue	1,000,000	3,297,063	9,217,635	24,834,206

Overview

Ship Thrifty builds technology for overlooked markets.

The team revolutionized the online package shipping process for consumers and then military-supporting nonprofits and companies.

Now we invented an all-in-one online platform for our same nonprofit and small businesses customer profiles so they thrive online without any tech skills or bills.

Our next evolution is to build a way for all our customers and all consumers to print shipping labels locally.

Company Milestones

- 2017: Built self-service shipping tools for consumer shippers.
- 2018: Built military tools for shipping military care packages.
- Today: Military, consumer, and small business shippers love our tools.
- Growing base of national and corporate partners.
- Provisional patents in place.

Market opportunities (U.S. only)



Problem: \$6.5B in annual counter shipping will move online.

Solution: Online Label Creation via shiphtrifty.com or our shipping buttons that can go on 350M websites.

Online Label Creation
TAM \$8.5B
SAM: \$3.2B
SOM: \$791M



Problem: 33.5M nonprofits and businesses can't win online.

Solution: Our all-in-one platform that empowers underdogs to reach, drive revenue, & ship online.

Web Suite Media Hub
TAM \$9.6B
SAM: \$4.3B
SOM: \$947M



Problem: 56% of Americans don't own a printer so they can't print shipping labels purchased online.

Solution: Build a kiosk printing network for the 56% who don't have a printer.

Kiosk Label Printing
TAM \$800M
SAM: \$352M
SOM: \$176M

Our products work together like flywheels

- Connect us to 45% of the U.S. population.
- Cultivate countless customer & partner acquisition points.
- Create a sticky web of cross sells.


It's time to add believers, backers, and builders to our company.

We've self-funded and incubated through the hard, time-consuming, expensive stuff.

Goals	Current state
Ramp marketing to drive awareness.	Marketing to the 99% who are on the fence or don't know we exist.
Fund team to grow partnerships and improve products.	Grow and add more large affiliate partnerships to reach millions.

Investment Inquiries Rob@shipthriftly.com
651-226-6283
calendly.com/robshipthriftly

Financial Projections



PARTNERS



SHULMAN
ROGERS

NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.



ANTHONY MILLIN, NEXT CHAIR & PARTNER, SHULMAN, ROGERS

Anthony Millin is the Chair of NEXT and a trusted legal and business advisor to startup, early-stage, and emerging growth companies. As a corporate and securities attorney, a successful serial entrepreneur, and a venture capitalist, Anthony brings a unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund-raising process, and to address the legal issues faced by a startup. Another specialized skill set Anthony brings to the table is his China-based experience, assisting early-stage and middle-market companies interested in conducting business in China or seeking direct foreign investment from China. Anthony also serves as a Venture Partner at Urban Us, a seed-stage VC firm. Contact Anthony at amillin@shulmanrogers.com.



AEG @enterprisegrowth

AEG is a "Time Machine" for business leaders. We accelerate development of trust, driving fast and efficient referrals to accelerate business development and growth. We are a values-based membership organization of three communities (1) CEOs of \$20M+ companies in diverse industries, (2) elite advisors in complementary disciplines, and (3) regional centers of influence including economic development, trade associations and media.



MARK HAAS, CEO, AEG @MarkHaas

Mark Haas is Co-founder and CEO of AEG (Association for Enterprise Growth), responsible for strategy, operations, and expansion of its communities to 30 cities nationally. He was previously President of ROM a strategy and operations management consulting firm, advising CEOs and boards to include leadership training for Tanzanian energy executives, developing curricula to train consultants in 40 countries for an international bank, crafting strategy and innovative business models for \$120 million nonprofit, merging two scientific associations, re-organizing a biomedical research agency, facilitating development of WWIV military strategy, and of facilitating a global R&D strategy for the US Navy.



MODUS CREATE @ModusCreate

We built our company with an ethos of open source, recruiting and retaining the best individual contributors, regardless of location. We are thought leaders who share what we learn and help steer the direction of our open source communities of practice.

We're not just dreamers or doers; we're partners and teachers. We help you instill a culture of learning, innovation, and unlocked potential throughout your organization.

In short, we help you transform your products, platforms, and processes to facilitate organisation-wide digital transformation.

PARTNERS



PAT SHERIDAN, CO-FOUNDER & MANAGING PARTNER, MODUS CREATE

Pat is focused on the intersection of design, technology, and business. He saw the need for a high-end product consulting firm built with open-source team design and the concept for Modus was born. Pat helps clients see new ways to tackle challenges with emerging technology and brings his unmatched passion to work every day. As a serial entrepreneur and active startup mentor, he's a co-organizer of NoVa.JS and NYC.JS. He is a 2011 graduate of Mind Share, received his MBA from Georgetown University, where he is currently an Entrepreneur-in-Residence, and holds a BFA from the Corcoran College of Art and Design, where he currently serves as an advisory council member for the George Washington University Columbian College of Arts and Sciences.



PRINCE WILLIAM COUNTY DEPARTMENT OF ECONOMIC DEVELOPMENT

The Prince William County Department of Economic Development and Tourism works hard to create a pro-business, globally-competitive environment that generates new, high-quality, and sustainable job opportunities for our residents and destination-driven attractions for our visitors. The department engages in a broad portfolio of services, partnerships, and strategic alliances to benefit the business community, including small businesses, startups, and entrepreneurs.



CHRISTINA WINN, EXECUTIVE DIRECTOR AT PRINCE WILLIAM COUNTY DEPARTMENT OF ECONOMIC DEVELOPMENT

Christina leads the Prince William County Department of Economic Development, catalyzing investment, retention, and redevelopment opportunities in the second largest county in Virginia. By positioning the county as a leader in the fast-paced, evolving economy of the Washington, D.C. region, we are shaping stages for expansion and collaboration in key target industries. With more than 20 years of economic development and private sector real estate experience, she is an expert in development programs including finance, incentives, and marketing. Prior to leading PWCDDED, she led Arlington's Economic Development business investment group, leading retention, recruitment, and entrepreneurial support.



REFRACTION @refractionpt

Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.



DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND @UMD_Dingman

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs "from the back of a napkin to the first \$1 million in financing."



KEIRETSU FORUM @KeiretsuAngels

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.

PARTNERS



FITCI – FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC @FITCInc

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Fredrick, MD, and 52 client companies.



THE BALTIMORE ANGELS @baltimoreangels

The Baltimore Angels is an angel investor group based in Baltimore, MD. Founded in 2009, its mission is to invest profitably in the regional entrepreneurial ecosystem and advance early-stage innovators to the next stage of capital formation. Its vision is to be the most trusted resource for angel capital investment and entrepreneurial mentorship in the Greater Baltimore region. A new generation of angel investing comes to Baltimore. If you are a tech entrepreneur or community-minded investor, please be in touch with Baltimore Angels. This is not your father's (or your uncle's) investment group.



MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Maryland-based tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.



STARTUP GRIND-COLUMBIA, MD @StartupGrindDC

Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.



ANGELS + LIFE.SCI INVESTORS

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a manager-led, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor world-class Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: tele-diagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.

PARTNERS



JEFF REID, FOUNDING DIRECTOR, GEORGETOWN ENTREPRENEURSHIP INITIATIVE, GEORGETOWN UNIVERSITY'S MCDONOUGH SCHOOL OF BUSINESS @Hoyapreneur

Jeff Reid is the Founding Director of the Georgetown Entrepreneurship Initiative and Professor of the Practice of Entrepreneurship at Georgetown University's McDonough School of Business. Reid is a catalyst for entrepreneurship and a well-known leader in entrepreneurship education. In 2009, Reid launched the Georgetown Entrepreneurship Initiative to catalyze entrepreneurial thinking and activities across Georgetown University and impact the growing DMV startup community.



RYAN & WETMORE, P.C. @RyanWetmorePC

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/ Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.



PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



**ENTERPRISE TRANSFORMATION SOLUTIONS
INES LEBOW, FOUNDER AND PRINCIPAL @ilebow1**

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.



November 21 Attendees

As of 11 21 24

SPEAKERS			
First Name	Last Name	Title	Company
Tien	Wong	Founder and Host	CONNECTpreneur
Mark	Haas	CEO	AEG
Skylar	Rallison	Community Manager	CONNECTpreneur

PRESENTERS			
First Name	Last Name	Title	Company
Neal	Koller	Chairman and CEO	Alphyn Biologics, Inc.
Jeff	Miller	Chairman & CEO	Arcato
Steve	McCalmont	Founder and CEO	BraveHeart Wireless
Hooman	Banaei	Co-Founder and CEO	Everix Optical Filters
Jonathan	Cohen	President and CEO	20/20 Gene
Nicholas	Fratantonio	Owner and CEO	iByte
Amanda	Patanow	Chief Marketing & Product Officer	NeuroEM Therapeutics
Stephen	Bollinger	President and CEO	Ovala, Inc.
Alena	Shumova	Marketing Director	Quasi Robotics, Inc.
Michael	Haddix	CEO	Scout
Rob	Williamson	Owner and Co-Founder	ShipThrifty

ATTENDEES			
First Name	Last Name	Title	Company
Amer	Abukhadra	CEO	myCardioGuard
Zoe	Ackerman	Strategic Advisor to the CEO	Turingon, Inc.
Gulmohar	Ahluwalia	Founder CEO	Nyxara
Folahan	Akinyemi	MBA Candidate	Georgetown University
Ken	Allgood	Founder & CEO	HealthFlow Inc
Crescenzo	Amodio	CEO	Cav srl
Cliff	Anders	President	LeoSat Enterprises
Jill	Antweiler	VP, Product Development	Modus Create
Aileen Vanessa	Aramburo	Warehouse Associate	Lululemon
AJ	Attavar	Investor	NPS, Inc
Layla	Atya	Chief Risk Officer	Sitata
Darrin	Auito	Partner	HEA Law PLLC
Ruth	Austin-Okoro	Virtual Assistant	Ruth Austin
Ameera	Awais		
Mari Soonsoo	Bae	Co-founder	Ara Platforms
Bert	Baker	Co-founder & CEO	Tarc.co
Sandra	Bakut	Virtual assistant/project manager	
Hooman	Banaei	CEO / Founder	Everix Inc.
Trish	Barber	CEO	3WaysDigital
Vamshi	Bathini	Founder	
Urvashi	Batra	Founder - Product Lead	EcoF:re
Jay	Beam	Managing Director	Adasel Global Partners LLC
Abdel Wahed	Bendaoua	CEO	EXINS
Karen	Bertrand	Owner	ClearCloud Bookkeeping LLC
Victor	Beshidze	CEO	VB Solutions
Jaheer	Bijani	Founder and CEO	
Bry	Bird	Freelance Designer	Hi This Is Bry
Charlie	Birney	Founder	Podville Media
Steve	Bisset	CEO	Terrajoule Energy Inc.
Karl	Bodin	CEO	Arrowhead Capital LLC
Amory	Bodin	CEO	Bodin Capital
Valentino	Bofede	Business Analyst	Vtino Global Services
Stephen	Bollinger	Founder and CEO	Ovala, Inc.
Ilia	Borishchev	CEO	VIBRAINT
Johannes	Breukers	CEO	First Choice Bio, Inc.
Johannes	Breukers	CEO	First Choice Bio, Inc.
Stanley	Brock	President	Brock Dev Co
Sasha	Brodzka	brand & web designer	La Sashata Design Studio
William	Brucato	CEO / President	Byrne and Bruce, LLC
Naana Ama	Bruce		American University
John	Bulicek	Managing Director	Cambridge Wilkinson
Wade	Byrd	Founder/CEO	QEPR, Inc
Sandra	Cai	Founder	Plurall AI
Antonio	Canovas Alvarez	Business Developer	Inspiralia
Christian	Carello	Founder, CEO, + Angel Investor	EnvisionIt Consulting, LLC
Joe	Carlin	Principal	JOoXeone Capital
Doug	Carney	Investor	
Sue	Carr	CEO	CarrTech Corp

Stephen	Carter	COO	TRAXyL, Inc.
Karina	Castagna		
Hepzel	Castro	Independent Consultant	HCH Consulting
Zakiya	Charles	CEO	Hyper life llc
SaiKiran	Chebolu	Manager	Olympus
Chris	Chen	Title	Company
Anthony	Chernykh	Chief Business Officer	Neomarkets Group
Nelson	Chick	CAO	Foil Flyer
Jason	Chou		
Evgenii	Chupanov	President	Chupanov Family Fund LP
Will	Classen	AVP	Colliers
Tanyi	Colette	Founder	NKINDLE
Victoria	Collins	Founder	Buzzy Rocket
Scott	Collins	CEO	AIG
Andi	Contreras	Visionary and Founder	BeyondBorders Pro Solutions LLC
Colleen	Crangle	Founder/Partner	Converspeech LLC
Larry	Cynkin	Founder and Consulting CTO	GreenBar
Hank	Dearden	Principal	Group 3
Paramita	Debbarman	Founder	PDCC
Hector	Del Castillo	Chief Product Officer	Byond
Talabiou	Diallo	Founder and CEO	Sentier
Dejana	Dua	Partner	Anexa Capital
Radha	Duttgupta	VP, Clinical Affairs	Nucleix
Peter	Egli	Executive Director	LGT Capital Partners
Bradley	Enneking	CIO	HTLF
Ahmad	Erfan	COO	Viridis Research Inc.
Maria	Ermolova	Investment Banking Managing Director	Weild & Co.
Azin	Etemadimanesh	CEO	Dione.Health
Peter	Ettinger	Partner	The 7914 Group
Herb	Ezrin	CEO & President	Potomac Business Group
Kim	F	Advisor	
Sina	Faridimehr	Founder and CEO	Energetics
Christine	Foord	Interior Designer	Foord Design Studio
Uriel Io	Foronda	Executive Assistant	Aquillius
Cindy	Fraley	Membership Director	Keiretsu Forum Southern California
Dorothy	Fulop	Fractional CMO	dorothyfulop.com
Sathish Kumar	Gangadhar	Associate	SBSS & Associates
Sristika	Gautam	Founder	Nester Skill Learning.
Soma	Gecse	Analyst	Freelancer
Tom	Ghiglione	Investor Relations Manager	TechBricks S.R.L.
Walid	Ghodbane	Accredited investor	Private
Gregory	Giammittorio	Partner	Potomac Law Group PLLC
Michael	Gilday		
Andrew	Goldsmith	Managing Partner	Mooring Partners
Douglas	Goldstein	Managing Director	iConecto.com
Joshua	Greenberg	Managing Consultant	Astral Partners International
Yoav	Greenberg	Senior Consultant	Astral Partners International
Mirta	Grifman	VP Clinical Development	Biosplice Therapeutics
Yulia	Gufranova	CEO	Solvada
Dean	Gultula	Managing Director	Devvara 2014
Bobby	Gupta	Founder & CEO	Votal.ai
Mark	Haas	CEO	AEG
Allen	Hakimi	Managing Director	Technomark Life Sciences
Fizie	Haleem	Business Soutlions Manager	Montgomery College WDCE
Malcolm	Handelsman	ED	DIR
Michael	Hanson	Consultant	Optimum Dynamics LLC
Chris	Harrises	President	Technical Solutions, inc.
Morgan	Hartrich		Cleveland Institute of Art
Qaizar	Hassonjee	Managing Partner	Angel star ventures
Claude	Hayn	CEO	AdJumps
Quinn	Heidenreich	Managing Partner	Allied Strategic Partners LLC
Browning	Herbert	MD	Ringbolt Capital
Michael	Higgins	Founder and CEO	DHML Connect
Tadayoshi	Hirata	Investment Lead	Astellas Venture Management
Dalibor	Hodko	CEO	Nexogen, Inc.
Fatemeh	Hosseini	Director	Georgetown
Mike	Huska	Fractional Chief Technology Officer	Vistra Business Solutions
Paul	Iacovacci	CIO	Enascor Capital
Tracy	Inc	COO	NeuroEM Therapeutics Inc
Mahesh	Inturi	Founder	Syncaru
Dave	Izuka	Venture Accelerator	Venture Acceleration and Incubation Services
August	Johnson	VC Analyst	Aquillius
Alan	Jordan	Founder	NLP
Thomas	Jueng	Sr. Managing Director	Samsung Ventures America

Alan	Kadish	CEO	InvestorMatch.ai
Ayush	Kala	Associate Product Manager	3advance
Alexandra	Kapelos-Peters	Founder and CEO	Cansulta
Michael	Kelly	CEO/Founder	Writeon, Corp.
Alvin	Kersting	CEO	Portfolio Operating Partners
Joe	Kessler	Managing Partner	Next-Stage Development Group
Ahmed	Khalil	Founder & CEO	ASCENSIA
Gene	Kim	Founder	DragonStartups
Sophie	Kim	Partner	Legacy VC
Ted	Koblick	VP of BD	Net-AV
Martin	Koev	Manager	Koev Brothers
Ellen	Koh	Director of Marketing	Raycom Communications Solutions, Inc.
Velibor	Koprivica	Chief Strategy Officer	Enfinia Growth Partners
Telcy Justice	Koudekikissa	Founder / CEO	Givify
Telcy Justice	Koudekikissa	Founder / CEO	Givify
Arina	Kozyr	Adjunct Prof	FCC
Victoria	Kozyreva	Sr Venture Associate	Go Global World
Jason	Kreisberg	Associate Director	Sanford Labs
M.D.	Kull	Founder and President	Amplifi Consulting and Executive Strategy
Rajnesh	kumar	Associate	KiwiTech
Joel	Lachance	CFO	BEMO Corp
Cash	Lafferty	Founder & CEO	Pando
Maria	Lamottke	VP Business Development	Bicoll
Maura	Lapoff	Co-Founder	Stilware
Julie	Lawrence	CEO	Eviset Inc.
Maxwell	Lawson	Document Imaging Specialist	University of Baltimore
Ines	LeBow	CEO/Founder	Enterprise Transformation Solutions, LLC
David	Lee	CEO	WealthRyse
Olia	Legoshina	Advisor to CEO	Gemba Finance Ltd.
Johnny	Li	Advisor	Telesair
Lenny	Lippert	Financial Advisor	Blunt-Lippert Financial Strategies Group
Tripti	Lochan	CEO	TriptiLochan
Cody	Locke	Chief Innovation Officer	Center for Advancing Innovation
Jingsen	Ma	Vice President	Dynaflow, Inc.
Sam	Maddali	CEO	UPNRX.com
Ameneh	Madjd	COO	D2Type
Samukele	Mafara	Founder	Sam Capital Investments
Pinaki	Majhi	Founder, President & CEO	Mona Brands, LLC
Eugene	Major	CEO	ImagineRx, Inc.
Annie	Malcolm	Founder and Owner	Lehigh Acres Coffee House
John	Malyevac	Sr. Business Development Manager	Ada
Maryam	Mark	Web Designer - Owner	Maryam's Mark and Co. LLC Art Social
Rayana	Marker	COO	CELLF BIO
Subhi	Marwari	Founder and CEO	Stealth startup
Arash	Mashhadi	Civil Engineer	Pennecon
Tudor	Matei	Leadership Coach	Lead Engineer Coaching
Mike	Mausteller	President	Buckeye Business Performance
Philip	Measor	CEO	Pacific Microdevices
Camila	Medina		Montgomery College
Maha	Mehanna	Vice President, Business Development & Portfolio	XGen Pharmaceuticals DJB, Inc.
Hetal	Mehta	Founder/ CEO	Gainfront, inc
Robert	Mendralla	President, Investments	RM Enterprises
Amy	Mittal		University of Waterloo
Judy	Mod	Founder + CEO	Innovations Domain, LLC
Max	Mohr	Fundraising Lead	StartEngine
Troy	Moore	Chief Scientific Officer	BioHSV Holdings
Nelsi	Morel	TA Specialist	SBM Management
John	Morgan	Managing Partner	Morgan Global
Ron	Morrell	Investor	Private
Jacquelyn	Mosier	Demo Expert/ Support Associate	Inflex
Chelsey	Moter	Founder	BLKBOOK
Joan	Mundua		
Sabareesan	Murugesan	CEO	Sandal Tree Soft
Charles	Nahabedian	CEO	VK Digital Health
Raghav	Nayar	Investor Relations	Vaajra Consulting
Thomas	Nedder	CEO	Neato robotics
Thomas	Nedder	CEO	Neato Robotics
Osric	Nehamiah	Founder	The Remote Nest
Victoria	Neils	Style Coach & Life Coach	Inner Radiance & Style
Paul	Nemirovsky	Advisor	Advisory
Jolie	Nguyen	LP	A26
Doug	Nguyen	Founder	Gigmarket
Paul	Nolde	Executive Director	757 Angels
Martin	Nsanta	Founder	Ibubbly health

Dennis	oneill	CEO	Oneillcapitaladvisors.com
Chuck	Papageorgiou	CEO	NeuroEM Therapeutics
Jay	Park	Managing Partner	Linkorus, LLC.
Nathan	Pascarella	Director	Hypertherm Ventures
Allison	Pasque	Founder	Detroit Bird LLC; APosteriori LC
Amanda	Patanow	Chief Marketing and Product Officer	NeuroEM Therapeutics
Dilan	Patel	Founder & Chief Editor	DIL Media LTD
Kushtrim	Peci	Financial Advisor	Merrill Lynch
Mhiel	Peralta	Chief of staff	Royal belle equitu
Venkata Reddy	Pilli	Director	
Sharon	Plummer	Founder	Save The Planet Working Group
William	Podd	President	Landmark Family Office
Zach	Pogue	Owner	Pogue Consulting
Leslie	Poole	Principal	LE-POOLE GROUP
Leslie	Pound	Founder	TaDa Labs
Joel	Price	VP of Product Innovation	Core Source Technologies
Tina Guanting	Qiu	CEO Founder	Ophthalmic Therapeutic Innovation LLC
Soheil	Raissi	CEO	Maptics
A	Raj	President	ARAR Technology
Damoder	Reddy	Investor	Chemical Angels
Teri	Reitan	President	Strategic Merger and Acquisitions
Victor	Rhoder	VP of Channels and Strategic Partnerships	AtWork Systems LLC
Alex	Rojas	Talent Advisor	Objective Recruiting
Jay	Rosanelli	CEO	Syenex
Robert	Rosenberg	President	S M C
Larry	Rosenfeld	Director	McLean Partners LLC
Arthur	Runno	Founder/CEO	Turingon, Inc.
Ellen	Runno	Founder/Chief Strategy Officer	Turingon, Inc.
Jason	Rupp	Wealth Consultant	Life Science Wealth
Jason	Rupp	Wealth Consultant	Life Science Wealth
Ruby	Russell	Founder	RR Distinctive Beddings
Ruby	Russell	Founder	RR Distinctive Beddings
Paul	Russo	CEO	K2x
Nader	S	Engineer	Genex
Harilbabu	S	Assistant Professor	SNS College of Engineering
Paula	Saidy	CEO	HireAthena Inc.
Basel	Salahieh	CEO	Vimmerse
Hans Miguel	Sanchez Nagel	Account Manager	Inspiralia
Andrey	Sanenko	Head of Delivery	VReal Soft
Cindy	Santa Cruz	CEO	Lady Patch
Chris	Sarlo	Founder	Life Science Wealth
Eric	Schuur	CEO	Hepatx Corporation
Gerhard	Schwandt	Certified Executive Coach +	Gerhard B. Schwandt
Joel	Scott	Founder	SV Academy
Mahesh	Seethagari	Innovation Specialist	ZIVA Consulting
Mario	Shaffer		
Mario	Shaffer		
Shaishav	Shah	Founder	Softvan Group
Mitesh	Shah	Founder	
Hema	Shah	CFO	GBTA
Terry	Sheldon	Executive Virtual Assistant	Freelance
Rebecca	Shewbridge	M&A Lead	Opus8
Chris	Shiver	CEO	Adventure Headquarters
Todd	Shoemack	CEO	VCC
Gurbaksh	Singh		Lambton
Navdeep	Singh	Machine operator	Polar pak
Ranjit	Singh		Lambton college
Sam	Sofer	President	BioOx AIR & WATER SOLUTIONS
Tom	Solitario	Technology Scout	Tom, Inc.
Karen	Sorber	CEO	Micronic Technologies
Rose	Spencer	Founder/CEO	Phoenix Rising Media & Productions
Ajay	Srivastava	President	ekuber Ventures Inc
Richard	Staats	Board of Advisors	IMEROPEX
Ernest	Stern	Partner	CM Law PLLC
Nathan	Stevenson	CEO, Founder	ForwardLane
Paul	Stewart	CEO	Tranexamic Technologies
Maxwell	Suchitha	Director	Adonia infotech export pvt Ltd
Ning	Sung	Investor	Sand Hill Angels
Tom	Swanson	President	TJSwanson Co.
Yajaira	Taboada	Marketing Coordinator	TechAID
Venkat	Tadakamalla	President	ITSYS Inc
William	Taffa	Entrepreneur Director	Keiretsu Forum SoCal
Andrew	Tansil	Founder	Elevated Holdings Group
Andrew	Tansil	Owner	Elevated Holdings Group

Tsegereda	Tefarie	Senior Strategic Planner	AFDW
Rahul	Tevatia	Contract	
Jayant	Thatte	CEO	Turiya Therapeutics
Andrew	Tsintsiruk	CEO	Rohic Inc.
Jonny	Tyers	MD	Threatplane
Kyo	Ueda	CEO/Founder	Mirror Mii Inc.
Laarni	Valledo	Business Development Manager	GSG4
Christina	Van	Senior Scientist	Navega Therapeutics
Joel	Van Treese	President	Electra Products Agency
Carol	Vancleef	CEO	Luminous Group
Karl	Varner	Managing Director	Varner Intl
Roy	Vella	Managing Director	Vella Ventures
Marcelo	Vieira	Investment Analyst	Cadence Bank
Jim	Voeller	Patent Attorney	Maier & Maier
Tom	Vogelsong	Startup Scout	K2X.capital
Jordan	Wahbeh	Managing Partner	SV Venture Group
James	Walker	CEO	Integrity First Academy
Michael	Walsh	CEO	Citizen.WIN
Mei	Wang	CEO	Instapath Inc.
Dong	Wang	CEO	Enrich Biosystems
Ping	Wang	Founder	Ansir
Kyoko	Watanabe	Managing Director	DEFTA Partners
Mike	Watson	CEO	miruminvest.com-above10x
Barry	Weinbaum	Financial Service Professional	New York Life
Linda	Wernick-Cassell	Sr. Advisor to Pres/CEO; Board Chair	Melwood
Skip	West	President	MAXSA Innovations LLC
Greg	Whelan	Innovation Advisor	Greywale Advisors
Todd	Wiggins	Admin	MeetMeDC.com
Laurie	Wiggins	CEO	Byond
David	Willard	Private Wealth Advisor	Goldman Sachs
Pete	Wills	Owner	Manport LLC
Tom	Wills		Manport LLC
Karolina	Wojtas	Director of Strategic Development	Everix Inc.
Eric	Wong	Founder	Myko Labs, LLC
Venus	Wong	Chief Solutions Officer	Eviset, Inc.
Amy	Wood	Program Manager	Pepperdine University
Florence	Wood	Director	JRC Services Pro
Thomas	Wright	CEO	Horizon
Jim	Wu	Founder	SaniMed Science Group
Guoqiang	Xing	CEO	Lotus Biotech.com LLC
Yi	Yang	Managing Partner	WaterStar Capital
Susan	Young	Principal	Blue Dog Consulting LLC
John	Yung	Investment Analyst	Framework Venture Partners
Mo	Zag	Founder	CDA
Carrie	Zhang	CEO	Markeny
Tammie	Zhao	Founder	Decolonize with T
Yan	Zhao	Founder	Drive Medical Inc

THANK YOU TO OUR PREP TEAM



LAURA HILL
SVP
Equifi



INES LEBOW
CEO
Enterprise Transformation
Solutions



MARISSA LEVIN
CEO
Successful Culture
International



BOB LONDON
CEO
Chief Listening Officers



JET LU
Customer Solutions
Amazon Web Services



JACKIE LUO
Founder
BAM Advisory



MICHELLE MILLER
Founder
MRM Consulting



JOHN MORGAN
General Partner
Morgan Global



EVAN SHUBIN
Pres. and Founder
Results.now, Inc. and
Candlelight Partners



MALI PHONPADITH
CEO
SOAR Community
Network



MICHAEL RIEMER
CEO & Board Member
Vocinity

SPONSORS



Angels + Life.Sci Investors



THE CENTER FOR ADVANCING INNOVATION



WANT TO PRESENT OR SPONSOR AT OUR VIRTUAL EVENTS?

Email Skylar Rallison at
srallison@opus8.com
for more information

2024 Virtual Calendar

Dec. 19

2025 Virtual Calendar

Jan. 30	March 27	April 24
May 29	June 26	July 31

CONNECT WITH US!





VIRTUAL AND IN-PERSON

CALL FOR PRESENTERS

Unprecedented
**Networking
sessions**
before, during, and
after each event

Free lifetime
admission
to all
CONNECTpreneur
Forums

Post-event recap to
**206k business
leaders**
in our Community

SCAN HERE FOR
THE IN-PERSON
BROCHURE:



SCAN HERE FOR
THE VIRTUAL
BROCHURE:



Get funded with our



Private Investor Platform



One of the nations largest investor communities of 4,500+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.

**Exclusive,
cost effective,
& reliable**

**Vetted, qualified,
accredited
Investors**

**We
guarantee
our results**



**View the full
brochure**

Tien Wong
CEO
twong@opus8.com

Skylar Rallison
Community Manager
srallison@opus8.com

BOUTIQUE FEEL, ENTERPRISE SCALE

Launch new products into the hands of your customers and change the way your company builds software. We provide full stack, full lifecycle teams to help you hit your goals.


END-TO-END PRACTICES • STRATEGIC SUPPORT

PRODUCT DEVELOPMENT

- + Application Development
- + Application Modernization
- + Team/Staff Augmentation
- + UX/UI/Product Design
- + Smart Contract Verification
- + Language & Compiler R&D
- + Intelligent Applications
- + Product Strategy
- + AI Intelligent Apps

PLATFORM & CLOUD

- + Cloud and Infrastructure
- + Enterprise Architecture
- + PlatformOps
- + Developer Tooling and Experience
- + Security Operations
- + TestOps
- + Builds at Scale
- + Regulated Platform Development




DIGITAL STRATEGY

- + M&A Assessment
- + AI Strategy Roadmap
- + Customer Experience Strategy
- + Product Portfolio Review
- + Business Case Definition & Rapid Prototyping
- + Product Management Maturity
- + AI Experiment Design
- + Data Architecture
- + AI & Data Readiness

DIGITAL OPERATIONS

- + DevEx Transformation
- + Enterprise Service Management
- + Product, Project & Developer Tooling

PARTNERSHIPS ACROSS THE SDLC



REGISTER FOR OUR UPCOMING EVENTS

December 16

In-Person



December 19

Virtual



Healthcare

Investor Brunch

January 12, 2025
San Francisco, CA

